Skip to main content

Advertisement

Table 2 Medication use of 901 PD patients

From: Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China

Medication use Total Gulf of Bohai Changjian Delta Pearl-River Delta Mid-westArea P Value
  (n = 901) (n = 283) (n = 275) (n = 110) (n = 233)  
LED a 450 (350) 500 (330) 435 (360) 525 (353) 375 (330) 0.01
LD/DCI treatment, n (%) 737 (81.8) 227 (80.2) 231 (84.0) 100 (90.9) 179 (76.8) 0.01
  LD Dose, mg/d 375 (265) 375 (200) 375 (300) 375 (300) 375 (250) 0.81
  LD/DCI Duration, months b 29.5 (51.0) 36.0 (54.0) 34.0 (51.0) 21.0 (45.0) 16.0 (38.0) <0.001
Dopamine agonists, n (%) 296 (32.7) 98 (34.6) 83 (30.2) 53 (48.2) 62 (26.6) <0.001
  Duration, months b 12.0 (28.0) 18.0 (32.0) 9.5 (23.0) 12.0 (21.0) 8.0 (19.5) 0.004
Amantadine, n (%) 222 (24.6) 88 (31.0) 77 (28.0) 25 (22.7) 32 (13.7) <0.001
  Dose, mg/d 200 (0) 200 (0) 200 (100) 200 (0) 200 (100) 0.07
  Duration, months b 21.0 (43.0) 29.5 (62.5) 11.0 (34.0) 10.5 (21.5) 18.5 (53.5) 0.002
Anticholinergics, n (%) 169 (18.8) 43 (15.2) 64 (23.3) 15 (13.6) 47 (20.2) 0.04
  Dose, mg/d 4.0 (2.0) 4.0 (3.0) 3.0 (2.0) 4.0 (4.0) 4.0 (4.0) 0.02
  Duration, months b 23.0 (51.0) 38.0 (62.0) 25.0 (57.0) 17.0 (21.0) 20.2 (41.0) 0.23
Entacapone, n (%) 55 (6.1) 17 (6.0) 8 (2.9) 11 (10.0) 19 (8.2) 0.02
  Dose, mg/d 300 (200) 300 (200) 250 (200) 300 (200) 300 (100) 0.68
  Duration, months b 5.5 (14.0) 9.0 (14.0) 9.0 (20.0) 4.0 (5.0) 1.5 (6.5) 0.04
Selegiline, n (%) 87 (9.7) 36 (12.7) 36 (13.1) 13 (11.8) 2 (0.9) <0.001
  Dose, mg/d 5.0 (2.5) 5.0 (2.5) 5.0 (5.0) 5.0 (0.0) 5.0 (0.0) 0.63
  Duration, months b 15.0 (27.0) 24.0 (23.0) 12.0 (33.0) 7.5 (22.0) 15.0 (0.0) 0.87
All LD/DCI users (n=737)            
  Motor fluctuation, n (%) 137 (18.6) 47 (20.7) 50 (21.6) 11 (11.0) 29 (16.2) 0.09
  Dyskinesias, n (%) 63 (8.6) 22 (9.7) 15 (6.5) 11 (11.0) 15 (8.4) 0.49
  1. Abbreviations: LED: L-dopa/DCI equivalent daily dose; LD: L-dopa; IQ: Interquartile range.
  2. Values are given as Median (IQ) unless stated otherwise;
  3. a n = 806.
  4. b Data are available for duration of medication user: n = 726 for L-dopa, n = 267 for dopaming agonists, n = 211 for amantadine, n = 159 for anticholinergics, n = 46 for entacapone, and n = 65 for selegiline.